Gilead Sciences' Two Phase Three Trials Meet Primary Endpoints By: Benzinga via Benzinga April 15, 2016 at 06:53 AM EDT Gilead Sciences, Inc. (NASDAQ: GILD) disclosed detailed 48-week results of its two big phase three clinical trials to evaluate ... Read More >> Related Stocks: Gilead Sciences